EP1333862A2 - Methods of and pharmaceutical compositions for improving implantation of embryos - Google Patents
Methods of and pharmaceutical compositions for improving implantation of embryosInfo
- Publication number
- EP1333862A2 EP1333862A2 EP01978796A EP01978796A EP1333862A2 EP 1333862 A2 EP1333862 A2 EP 1333862A2 EP 01978796 A EP01978796 A EP 01978796A EP 01978796 A EP01978796 A EP 01978796A EP 1333862 A2 EP1333862 A2 EP 1333862A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- heparanase
- embryo
- effective amount
- contacting
- mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 238000002513 implantation Methods 0.000 title claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 33
- 210000002257 embryonic structure Anatomy 0.000 title claims description 27
- 108010037536 heparanase Proteins 0.000 claims abstract description 192
- 102100024025 Heparanase Human genes 0.000 claims abstract description 184
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 92
- 210000004291 uterus Anatomy 0.000 claims abstract description 79
- 230000032692 embryo implantation Effects 0.000 claims abstract description 32
- 210000002459 blastocyst Anatomy 0.000 claims description 33
- 238000000338 in vitro Methods 0.000 claims description 28
- 230000004720 fertilization Effects 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 claims 1
- 101150092805 actc1 gene Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 52
- 229920002971 Heparan sulfate Polymers 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 30
- 210000002744 extracellular matrix Anatomy 0.000 description 26
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 24
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 18
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 18
- 230000035935 pregnancy Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 15
- 108090000054 Syndecan-2 Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 13
- 210000002993 trophoblast Anatomy 0.000 description 13
- 229920002683 Glycosaminoglycan Polymers 0.000 description 12
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000009261 transgenic effect Effects 0.000 description 11
- 238000011830 transgenic mouse model Methods 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 229960002897 heparin Drugs 0.000 description 10
- 102000016611 Proteoglycans Human genes 0.000 description 9
- 108010067787 Proteoglycans Proteins 0.000 description 9
- 230000009545 invasion Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 230000013011 mating Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000008774 maternal effect Effects 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000027326 copulation Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 150000002016 disaccharides Chemical group 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011748 CB6F1 mouse Methods 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Chemical group O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- -1 oxonium ion Chemical class 0.000 description 3
- 230000028742 placenta development Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 108091016585 CD44 antigen Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 108010047481 uterine luminal fluid proteins Proteins 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710122462 65 kDa protein Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100219349 Mus musculus Cdh11 gene Proteins 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100032953 Trophinin Human genes 0.000 description 1
- 101710148378 Trophinin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002367 endolytic effect Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 108010006406 heparinase II Proteins 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000251 trophoblastic cell Anatomy 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the present invention relates to methods and pharmaceutical compositions for improving embryos implantation rate and, more particularly, to methods and pharmaceutical compositions for improving in vitro fertilization embryos implantation rate.
- Infertility and assisted reproductive technologies Treatment of infertility problems is a growing area of health care.
- IVF in vitro fertilization
- Infertility is understood to be the inability to conceive after six to twelve months of sexual activity without the use of contraceptives, depending on the age of the persons involved. Because infertility exerts extreme physical, emotional and financial stresses on those who are unable to conceive, there is a great need for improved aids for reproduction. These aids are typically referred to as Assisted Reproductive Technologies (ART). In vitro fertilization (IVF) followed by embryo transplantation:
- IVF In its simplest form, IVF consists of pharmaceutical stimulation of the female's ovaries to produce a large number of follicles. Eggs surgically harvested from these follicles are then mixed in the laboratory with the male's sperm. If fertilization is successful, the embryos are incubated for a short time and then transferred back to the female. If one of these embryos implants in the uterine wall, a successful pregnancy may follow.
- IVF intracytoplasmic sperm injection
- AH Assisted Hatching
- IVF procedures can also incorporate donor tissues, including sperm, ova and embryos, for those individuals who cannot produce their own.
- Proteoglycans are remarkably complex molecules and are found in every tissue of the body. They are associated with each other and also with the other major structural components such as collagen and elastin. Some PGs interact with certain adhesive proteins, such as fibronectin and laminin. The long extended nature of the polysaccharide chains of PGs, the glycosaminoglycans (GAGs), and their ability to gel, allow relatively free diffusion of small molecules, but restrict the passage of large macromolecules. Because of their extended structures and the huge macromolecular aggregates they often form, they occupy a large volume of the extracellular matrix relative to proteins. Murry RK and Keeley FW; Biochemistry, Ch. 57. pp. 667-85.
- Heparan sulfate proteoglycans are acidic polysaccharide-protein conjugates associated with cell membranes and extracellular matrices. HSPGs bind avidly to a variety of biologic effector molecules, including extracellular matrix components, growth factor, growth factor binding proteins, cytokines, cell adhesion molecules, proteins of lipid metabolism, degradative enzymes, and protease inhibitors. Owing to these interactions, HSPGs play a dynamic role in biology, in fact most functions of the proteoglycans are attributable to the heparan sulfate (HS) chains, contributing to cell-cell interactions and cell growth and differentiation in a number of systems.
- HSPGs heparan sulfate
- HS maintains tissue integrity and endothelial cell function. It serves as an adhesion molecule and presents adhesion-inducing cytokines (especially chemokines), facilitating localization and activation of leukocytes. HS modulates the activation and the action of enzymes secreted by inflammatory cells. The function of HS changes during the course of the immune response are due to changes in the metabolism of HS and to the differential expression of and competition between HS-binding molecules.
- HSPGs are also prominent components of blood vessels (Wight TN et al; Arteriosclerosis, 1989, 9: 1-20). In large vessels HSPGs are concentrated mostly in the intima and inner media, whereas in capillaries HSPGs are found mainly in the subendothelial basement membrane, where they support proliferating and migrating endothelial cells and stabilize the structure of the capillary wall.
- ECM extracellular matrix
- Heparanase - a GAGs degrading enzyme Heparanase - a GAGs degrading enzyme:
- GAGs Degradation of GAGs is carried out by a battery of lysosomal hydrolases.
- One important enzyme involved in the catabolism of certain GAGs is heparanase. It is an endo- ⁇ -glucuronidase that cleaves heparan sulfate at specific interchain " sites.
- GAGs glycosaminoglycans
- Sulfated GAGs include heparin, heparan sulfate condroitin sulfate, dermatan sulfate and keratan sulfate.
- Heparan sulfate and heparin are composed of repeated units of glucosamine and glucuronic/iduronic acid, which undergo modifications such as C5-epimerization, N-sulfation and O-sulfation. Heparin is characterized by a higher level of modifications than heparan sulfate.
- GAGs can be depolymerized enzymatically either by eliminative cleavage with lyases (EC 4.2.2.-) or by hydrolytic cleavage with hydrolases (EC 3.2.1.-). Often, these enzymes are specific for residues in the polysaccharide chain with certain modifications. GAGs degrading lyases are mainly of bacterial origin.
- Heparanase is defined as a GAG hydrolase which cleaves heparin and heparan sulfate at the ⁇ l,4 linkage between glucuronic acid and glucosamine. Heparanase is an endolytic enzyme and the average product length is 8-12 saccharides.
- heparin/heparan sulfate degrading enzymes are ⁇ -glucuronidase, ⁇ -L iduronidase and ⁇ -N acetylglucosaminidase which are exolytic enzymes, each one cleaves a specific linkage within the polysaccharide chain and generates disaccharides.
- table 8 the authors list two heparanases; platelet heparanase and tumor heparanase, which share the same substrate and mechanism of action. These two were later on found to be identical at the molecular level (Freeman et al. Biochem J. (1999) 342, 361-268, Vlodavsky et al. Nat. Med. 5(7):793-802, 1999, Hullet et al. Nature Medicine 5(7):803-809, 1999).
- Heparin and heparan sulfate fragments generated via heparanase catalyzed hydrolysis are inherently characterized by saturated non-reducing ends, derivatives of N-acetyl-glucoseamin.
- the reducing sugar of heparin or heparan sulfate fragments generated by heparanase hydrolysis contain a hydroxyl group at carbon 4 and it is therefore UV inactive at 232 nm.
- T and B lymphocytes, platelets, granulocytes, macrophages and mast cells with the subendothelial extracellular matrix (ECM) is . associated with degradation of heparan sulfate by heparanase activity.
- the enzyme is released from intracellular compartments (e.g., lysosomes, specific granules) in response to various activation signals (e.g., thrombin, calcium ionophore, immune complexes, antigens and mitogens), suggesting its regulated involvement in inflammation and cellular immunity.
- activation signals e.g., thrombin, calcium ionophore, immune complexes, antigens and mitogens
- heparanase may not only function in cell migration and invasion, but may also elicit an indirect neovascular response (Vlodavsky I et al; Trends Biochem. Sci. 1991, 16: 268-71).
- the ECM HSPGs provide a natural storage depot for bFGF. Heparanase mediated release of active bFGF from its storage within ECM may therefore provide a novel mechanism for induction of neovascularization in normal and pathological situations (Vlodavsky I et al; Cell. Molec. Aspects. 1993, Acad. Press. Inc. pp. 327-343, Thunberg L et al; FEBS Lett.
- IVF has several significant problems.
- the procedure is unpredictable.
- the ideal result of any IVF procedure is a single, live birth, a viable pregnancy occurs in only about 30 % of all procedures.
- IVF may result in a pregnancy with multiple embryos.
- twins and triplets pose relatively few risks beyond a single embryo pregnancy.
- the potential for problems, however, increases for higher order births. Selective embryo reduction is therefore often recommended for these cases which increases the psychological trauma for the parents.
- IVF Like unassisted reproduction, IVF begins with a source of sperm and ova. There is a virtually 100 % certainty of obtaining these materials, using donor tissues if necessary. Next, fertilization occurs, and good IVF laboratories typically have a fertilization success rate of about 75 %, using ICSI if appropriate. After a short incubation period, the resulting embryo is then introduced into the uterus, where implantation occurs. Implantation is generally the limiting factor in overall IVF success.
- Implantation itself, however, consists of several steps. First, the embryo must enter the uterine cavity. In normal reproduction, without ART, the embryo descends through the fallopian tubes. The embryo then comes into contact with some point on the uterine wall. Next, the embryo and wall surfaces fuse at the contact point. The uterine wall properties then change dramatically at the implantation site, thus allowing the embryo to become fully implanted. For IVF, the embryo is carried into the uterine cavity in a solution injected from a syringe inserted through the cervical canal.
- Improving the implantation rate would make the IVF process more reliable, more effective and yield many benefits. Improving the effectiveness of the IVF process above its current 30 % would reduce the need for repeat procedures, a critical factor considering the costs and stresses involved for the patients. Another benefit is that an improved success rate would make better use of the quite limited supply of donor ova and embryos. Improving the success rate would also further extend the supply of donor tissues by enabling some patients, particularly those who are older but otherwise healthy, to use their own tissues. Such patients would be more than willing to leave the donor program given the opportunity to have children of their own genetic basis. Yet another benefit is that by reducing the number of embryos required for a successful procedure, the incentive to overstimulate the ovaries is reduced, thereby reducing possible harmful side effects to the patient. Finally, improved implantation rate would eliminate the incentive to transfer large numbers of embryos back to the uterus, thereby preventing multiple births.
- AH assisted hatching
- tissue cultures Tissue cultures of uterine wall cells promise a more hospitable environment while still in vitro, with the hope that these conditions will prevail after transfer. None of these techniques has produced much success.
- ECM and bFGF in blastocyst implantation:
- trophectoderm attaches to the apical uterine luminal epithelial cell surface.
- Molecular anatomy studies in humans and mice, and data from experimental models have identified several adhesion molecules that could take part in this process: integrins of the alpha v family, trophinin, CD44, cad- 11, the H type I and Lewis y oligosaccharides and heparan sulfate.
- interstitial trophoblast invasion occurs requiring a new repertoire of adhesive interactions with maternal ECM as well as stromal and vascular cell populations.
- Human anchorage sites contain columns of cytotrophoblasts in which self-attachment gives way progressively to adhesion to ECM and then interstitial migration.
- fetal trophoblast cells invade and migrate into the maternal decidua. During this migration, trophoblast cells destroy the wall of the maternal spiral arteries, converting them from muscular vessels into flaccid sinusoidal sacs. This vascular transformation is important to ensure an adequate blood supply to the feto-placental unit. Both cell-cell and cell-matrix interactions are important for trophoblast invasion of the decidual stroma and decidual spiral arteries. Cell-matrix adhesions are mediated by specific receptors, mostly belonging to the family of integrins.
- metalloproteinases that facilitate matrix degradation and tissue remodelling.
- the trophoblastic cells of the blastocyst and of the placenta express an invasive phenotype. These cells produce and secrete metalloproteinases which are capable of digesting the extracellular matrix and invade it.
- the components of the ECM such as laminin and fibronectin, play an important role.
- the endometrial extracellular matrix is thus a potent regulator of trophoblast invasion.
- the invasion of extravillous trophoblast cells into the maternal endometrium is one of the key events in human placentation.
- the ability of these cells to infiltrate the uterine wall and to anchor the placenta to it as well as their ability to infiltrate and to adjust utero-placental vessels to pregnancy depends, among other things, on their ability to secrete enzymes that degrade the extracellular matrix.
- HSPGs are an integral constituent of the placental and decidual ECM. Because this proteoglycan specifically interacts with various macromolecules in the ECM, its degradation may disassemble the matrix. Hence, in the case of the placenta, this may facilitate normal placentation and trophoblast invasion. Incubation of cytotrophoblasts in contact with ECM results in release of ECM-bound bFGF. It was, therefore, proposed, yet so far never validated, that a cytotrophoblastic heparanase facilitates placentation, through cytotrophoblast extravasation and localized neovascularization. Goshen R et al; Mol. Hum. Reprod. 1996, 2(9): 679-84; Dempsey, L.A. et al. Trends Biochem Sci. 2000 Aug;25(8):349-51.
- Mammalian embryo implantation involves a series of complex interactions between maternal and embryonic cells. Uterine polypeptide growth factors may play critical roles in these cell interactions.
- bFGF is a member of a family of growth factors. This growth factor may be potentially important for the process of embryo implantation because it (i) is stored within the ECM and is thus easily available during embryo invasion; (ii) is a potent modulator of cell proliferation and differentiation; (iii) stimulates angiogenesis. Chai N et al; Dev. Biol. 1998, 198(1): 105-15. Relatively high concentrations of bFGF significantly enhance the rate of blastocyst attachment and of trophoblast spreading and promoted the expansion of the surface area of the implanting embryos.
- KGF Keratinocyte growth factor
- bFGF derived form the endometrial cells exert paracrine effects on the process of implantation by stimulating trophoblast outgrowth through their cognate receptors.
- mRNAs encoding bFGF were detected in all stages of the ovine preimplantation embryo, although the relative abundance of this transcript decreased from the one cell to the blastocyst stage, suggesting that it may represent a maternal transcript in early sheep embryos.
- bFGF The cellular distribution of bFGF was examined immunohistocheically in the rat uterus during early pregnancy (days 2-6). bFGF localized intracellularly in stromal and epithelial cells and within the ECM at days 2 and 3. It was distinctly evident at the apical surface of epithelial cells at days 4 and 5 of pregnancy. Concurrent with this apical localization, bFGF was present in the uterine luminal fluid, suggesting release of this growth factor from epithelial cells. Embryonic implantation was accompanied by increased intracellular bFGF content in luminal epithelial and decidual cells.
- bFGF is present within the implantation chamber on days 6-9 of pregnancy and may be involved in the decidual cell response, trophoblast cell invasion and angiogenesis. Wordinger RJ et al; Growth factors. 1994, 11(3): 175-86.
- heparanase DNA in animal cells Stably transfected CHO cells expressed the heparanase gene products in a constitutive and stable manner.
- Several CHO cellular clones have been particularly productive in expressing heparanases, as determined by protein blot analysis and by activity assays.
- the heparanase DNA encodes for a large 543 amino acids protein (expected molecular weight about 65 kDa) the results clearly demonstrate the existence of two proteins, one of about 60-68 kDa and another of about 45-50 kDa. It has been previously shown that a 45-50 kDa protein with heparanase activity was isolated from placenta, Goshen, R. et al. Mol.
- the 65 kDa protein is the pro-enzyme, which is naturally processed in the host cell to yield the 45 kDa protein.
- the p50 was found to be active and the p65 protein was not active, further suggesting that the p50 is the active enzyme, and the p65 is a pro-enzyme.
- heparanase to which an active form of heparanase is externally adhered, either cells genetically modified to express and extracellularly present or secrete heparanase, or cells to which purified heparanase has been externally added, are much more readily translocatable within the body of experimental animal models, as compared to cells devoid of externally adhered heparanase.
- Inactive pro-heparanase can be processed by endogenous proteases into its active form, once adhered to cells.
- heparanase can be used to assist in introduction of biological materials, such as cells and tissues into desired locations in the bodies of patients.
- a method of improving embryo implantation comprising contacting an embryo with an effective amount of heparanase and implanting the embryo in a receptive uterus.
- a method of improving embryo implantation comprising contacting a receptive uterus with an effective amount of heparanase and implanting the embryo in the receptive uterus.
- a method of improving embryo implantation comprising contacting a receptive uterus with an effective amount of heparanase, contacting an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.
- contacting the embryo with an effective amount of heparanase is in vitro.
- contacting the embryo with an effective amount of heparanase is in utero.
- the embryo is generated in vitro via in vitro fertilization (IVF).
- IVF in vitro fertilization
- contacting the receptive uterus with the effective amount of heparanase is concurrent to implanting the embryo in the receptive uterus.
- an embryo of, for example, 4-30 cells immersed in a solution containing, and/or coated with, exogenous heparanase.
- a pharmaceutical composition comprising, as an active ingredient, an effective amount of heparanase, the pharmaceutical composition is designed for intra-uterine application.
- a pharmaceutical composition comprising, as an active ingredient, an effective amount of heparanase, the pharmaceutical composition is designed for application to an embryo in vitro.
- an embryo growth composition comprising an effective amount of nutrients for embryonic growth and an effective amount of heparanase for assisting in embryo implantation.
- the heparanase is a mature heparanase.
- the heparanase is a pro-heparanase, cleavable into mature heparanase.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing methods and compositions which increase the probability of embryo implantation.
- FIG. 1 demonstrates the effect of heparanase on embryo implantation in mice.
- Pseudopregnant ICR mice were divided into 3 groups, Group 1 mice were implanted with untreated blastocysts (o, control), Group 2 mice were implanted with heparanase treated blastocysts (x, embryo), Group 3 mice were implanted with untreated blastocysts following intrauterine injection of 5 ⁇ l of heparanase (4 ⁇ g heparanase per uterine horn) ( ⁇ , uterus).
- heparanase 4 ⁇ g heparanase per uterine horn
- the present invention is of methods and pharmaceutical compositions which can be used to improve embryos implantation rate.
- the present invention can be used to improve in vitro fertilization embryos implantation rate. Improving embryo implantation rate would make the IVF process more reliable, more effective and yield many benefits. Improving the effectiveness of the IVF process above its current 30 % would reduce the need for repeat procedures, a critical factor considering the costs and stresses involved for the patients. Another benefit is that an improved success rate would make better use of the quite limited supply of donor ova and embryos. Improving the success rate would also further extend the supply of donor tissues by enabling some patients, particularly those who are older but otherwise healthy, to use their own tissues. Such patients would be more than willing to leave the donor program given the opportunity to have children of their own genetic basis.
- a method of improving embryo implantation comprises contacting an embryo with an effective amount of heparanase and implanting the embryo in a receptive uterus.
- embryo refers to the cell mass resulting from fertilization of an oocyte with a spermatocyte, either in vivo or in vitro, and which is suitable for implantation in a receptive uterus.
- fertilization is accomplished either by conventional intercourse or artificial insemination
- in vitro fertilization is accomplished either by contact with sperm or sperm cells or via intracytoplasmic sperm injection (ICSI).
- An embryo which is useful for implantation according to preferred embodiments of the present invention includes various stages between a two-cell embryo and a blastocyst.
- receptive uterus refers to a uterus of a female mammal that is ready for embryo implantation.
- receptive uterus In humans there are well established protocols for transforming a uterus into a receptive uterus. Further details can be found in "A textbook of in vitro fertilization and assisted reproduction: the Bourn Hall Guide to clinical and laboratory practice", Peter R Brindsen; or in the “Handbook of IVF", Trounson Alan & Gardner DK. In animals, more information can be found in the "Applied animal reproduction", H. Joe kBearden, John W Fuquay; and in the “Manipulating the Mouse Embryo - A Laboratory Manual", Hogan Beddington & Costantini Lacy.
- heparanase refers to an animal endoglycosidase hydrolyzing enzyme which is specific for heparin or heparan sulfate proteoglycan substrates, as opposed to the activity of bacterial enzymes (heparinase I, II and III) which degrade heparin or heparan sulfate by means of ⁇ -elimination.
- the heparanase can be natural (purified) or recombinant and optionally modified, precursor (e.g., pro-heparanase or pre-pro-heparanase) or activated (e.g., mature heparanase) form, as described in, for example, PCT US98/17954 and PCT/US99/09256, which are incorporated herein by reference.
- precursor e.g., pro-heparanase or pre-pro-heparanase
- activated e.g., mature heparanase
- the concentration and source of heparanase used may vary. Depending on incubation time, heparanase at concentrations of 0.1 ⁇ g/ml to 1 mg/ml can be employed. Presently preferred concentrations are 1 ⁇ g ml to 100 ⁇ g/ml.
- purified includes also enriched.
- Methods of purification/enrichment of heparanase are well known in the art. Examples are provided in U.S. Pat. Application No. 09/071,618, filed May 1, 1998, in Goshe R et al. Mol. Human Reprod. 2, 679-684, 1996 and in W091/02977, which are incorporated herein by reference.
- natural refers to an enzyme of a natural origin.
- the term "recombinant” refers to an enzyme produced via genetic engeneering techniques.
- any enzyme such as heparanase, refers both to the inactive pro-enzyme form and to its processed active form.
- the method comprises contacting a receptive uterus with an effective amount of heparanase and implanting the embryo in the receptive uterus.
- the method comprises contacting a receptive uterus with an effective amount of heparanase, contacting an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.
- the present invention can also be used as a means of improving implantation success in a conventional conception process.
- intrauterine application of heparanase prior to or during conventional conception is envisaged.
- contacting the embryo with an effective amount of heparanase can be achieved in vitro, ex vivo, of in uterus.
- the embryo is generated in vitro via in vitro fertilization, is removed from a uterus of a donor female or is generated in the receptive uterus via conventional conception. According to preferred embodiments of the invention contacting the receptive uterus with the effective amount of heparanase precedes implanting the embryo in the receptive uterus.
- contacting the receptive uterus with the effective amount of heparanase is concurrent to implanting the embryo in the receptive uterus.
- an embryo between 2 cells and a blastocyst immersed in a solution containing, and/or coated with, exogenous heparanase.
- exogenous heparanase means heparanase as this term is defined herein added beyond and over any amount of heparanase which may be present naturally.
- a pharmaceutical composition comprising, as an active ingredient, an effective amount of heparanase.
- the pharmaceutical composition according to this aspect of the present invention is designed for intra-uterine application.
- the pharmaceutical composition comprise, in addition to heparanase, a carrier, typically, a saline solution, approved for intrauterus application.
- the pharmaceutical composition according to this aspect of the present invention may also include additional active ingredients, such as, but not limited to, leukocyte inibitory factor (LIF).
- LIF leukocyte inibitory factor
- the pharmaceutical composition according to this aspect of the present invention is contained in a container or dispenser adapted for intrauterus application.
- Such containers include an elongated neck or dispenser capable of reaching the uterus via the vagina and cervix.
- the pharmaceutical composition according to this aspect of the present invention is identified for use in intravaginal application, in IVF procedures, and/or in embryo implantation procedures.
- local application is presently preferred, systemic (e.g., via injection or oral application) heparanase application may also be useful in implementing the present invention.
- vaginal suppositories is also envisaged.
- a pharmaceutical composition comprising, as an active ingredient, an effective amount of heparanase.
- the pharmaceutical composition according to this aspect of the present invention is designed for application to an embryo in vitro.
- the pharmaceutical composition comprises, in addition to heparanase, a carrier, typically, a saline solution, approved for immersing embryos during IVF procedures.
- the pharmaceutical composition according to this aspect of the present invention may also include additional active ingredients, such as, but not limited to, LIF.
- the pharmaceutical composition according to this aspect of the present invention is contained in a disposable container.
- the pharmaceutical composition according to this aspect of the present invention is identified for use in IVF procedures, and/or in embryo implantation procedures.
- an embryo growth composition comprising an effective amount of nutrients for embryonic growth and an effective amount of heparanase for assisting in embryo implantation.
- Additional active ingredients may include LIF.
- the nutrients used are typically those included in IVF culture medium, as described in, for example, "A textbook of in vitro fertilization and assisted reproduction: the Bourn Hall Guide to clinical and laboratory practice", Peter R Brindsen; or in the "Handbook of IVF", Trounson Alan & Gardner DK.
- the present invention successfully addresses the shortcomings of the presently known configurations by providing methods and compositions which increase the probability of successful embryo implantation.
- High level constitutive expression of heparanase was driven by chicken beta-actin promoter.
- the plasmid pCAGGS (Niwa, H et al. Gene 108: 193-200, (1991) was modified to contain a unique EcoKL site at position 1719.
- An Xbal-EcoBI 1.7 kb fragment, which contained the entire open reading frame of human heparanase was cloned into the compatible sites of the vector.
- the plasmid pCAGGS-Z ⁇ was digested with Sail and Pstl in order to isolate the expression cassette and eliminate bacterial DNA sequences.
- the resulting fragment contained the CMV-IE enhancer, chicken ⁇ -actin promoter and hpa cDNA followed by a rabbit ⁇ -globin poly adenylation site.
- the DNA fragment containing the hpa expression cassette was injected into fertilized eggs, derived from C57BL x BalbC breed.
- fertilized eggs derived from C57BL x BalbC breed.
- the isolation of fertilized eggs, injection of DNA and transplantation of blastocysts were conducted by the Department of cell biochemistry - the transgenic unit at the Hadassah Medical School, Jerusalem according to a protocol adapted from Hogan et al. Manipulating the Mouse Embryo A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1994.
- tail fragments were incubated overnight at 55 °C in a lysis buffer (8 M urea, 0.2 M Tris-HCl, 0.4 M NaCl, 20 mM EDTA, 1 % N-Laurylsarcosine, 10 ⁇ g/ml proteinase K).
- a lysis buffer 8 M urea, 0.2 M Tris-HCl, 0.4 M NaCl, 20 mM EDTA, 1 % N-Laurylsarcosine, 10 ⁇ g/ml proteinase K.
- the dissolved tissue underwent phenol extraction and ethanol precipitation, to l o obtain a highly purified genomic DNA.
- the integration of the human heparanase cDNA in the mouse genome was verified by PCR using two sets of primers.
- the first couple was designed to amplify the 5' region of the transgene. It included a ⁇ -actin promoter specific primer (designated 5'-pCAGGs) 5'-ATAGGCAGCTGACCTGA-3'
- human hpa specific primer (designated Hpl-300) 5'-TGACTTGAGATTGCCAGTAACTTC-3' (SEQ ID NO:2).
- the second primers set was designed to amplify the 3' region of the transgene. It included a human hpa specific primer (designated Hpu-830)
- PCR conditions were as follows: 2 minutes at 95 °C followed by 33 cycles of 15 seconds at 95 °C, 1 minute at 58 °C and 1 minute at 72 °C.
- mice 25 in their genome as revealed by a PCR reaction specific for the human hpa cDNA. Founders were mated with C57B1 mice to create FI mice and those were mated among themselves to create F2 mice. Homozygous F2 mice from each Go line were identified by Southern blot analysis and a quantitative PCR assay. Homozygousity was verified by mating with C57B1 mice, where all the 30 pups were positive heterozygous. All founder transgenic mice were back crossed with C57BL mice in order to establish C57B1 transgenic mice with a pure genetic background.
- mice bearing the human heparanase gene were mated and their litter size recorded.
- Transgenic and normal, 8 weeks old, C57BL mice were mated.
- the litter size per female and number of pregnancies per group were recorded. Two separate experiments were conducted. The results are summarized in Table 1 below.
- N/N normal females
- M normal males
- T/T(G1) transgenic Gl
- Gl transgenic Gl
- ICR mice 50 female and 17 male ICR (CD-I ® ) mice, about 8-12 weeks of age at study commencement and 50 female and 20 male CB 6 F1 mice, about 6-8 weeks of age at study commencement were used.
- ICR mice were used to obtain pseudopregnant females, whereas CB 6 F1 mice were used to obtain transplantable blastocysts.
- Test animals were kept under environmental controlled housing conditions throughout the entire study period and were maintained in accordance with Harlan Biotech Israel (HBI) approved Standard Operation Procedures (SOP's). At the termination of a three days acclimatization period, ICR female mice were individually identified by ear notching.
- Heparanase CHO-p65 heparanase (1.693 mg/ml; Batch No. 11-1) was used in all experiments performed. CHO-p65 heparanase was prepared according to the the protocol described in WO 01/7297. The enzyme was diluted in DMEM + 5 % FCS, 1.5:100 (final heparanase concentration 25 ⁇ g/ml) for the treatment of blastocysts. The enzyme was diluted with distiled water for intauterine injection, 1 :2.2, to receive a final concentration of 0.8 mg/ml heparanase. Additional materials:
- Gonadotropin (hCG) (040K1223) were purchased from Sigma-Israel
- DMEM with 4.5 mg/D-Glucose (116270); and heat inactivated Fetal Calf Serum (515412) were from Beit Haemek (Kibbutz Beit
- ICR male mice were anesthesized by intraperitoneal injection of Avertine (0.5 ml/mouse).
- a small transverse skin incision was made at a point level with the top of the legs and then a similar size transverse incision in the body wall. Both testes could be reached through the one incision.
- the fat pad of one of the testes was pulled out and the testis, vas deferens and epididymis accompanied it.
- the vas deferens was cut at two locations, 4-5 mm apart, and the testis was placed back inside the body wall. The same steps were repeated for the other testis.
- the skin was then sutured. 14 days following vasectomy mice were ready for mating.
- Pseudopregnant ICR mice were prepared by mating ICR female mice in natural estrus with vasectomized sterile ICR male mice, placing 3 females in a cage with one male. In the following morning the females were checked for a copulation plug. Female mice with no copulation plug were sacrificed.
- Superovulated females CB 6 F1 were used to obtain a sufficient number of blastocysts.
- the females were subjected to intraperitoneal injection of 0.1 ml (5 IU) Pregnant Mare's Serum (PMSG) on 11 a. m. 48 hours later the same females were injected intraperitoneally with 0.1 ml (5 IU) of Human Chorionic
- hCG Gonadotropin
- the superovulated CB 6 F1 female mice were sacrificed by dislocation and the abdominal cavity were opened. Following removal of uterus by cutting across the cervix and below the junction with the oviduct, the uterus were placed in a small volume of DMEM medium supplemented with 5 % fetal calf serum. Each horn were flushed using 25G hypodermic needle, inserted into the cut cervix, and a syringe with 1 ml of the above medium. A total of 288 embryos at a blastocyst stage were collected.
- blastocysts collected were placed in serum containing heparanase (25 ⁇ g/ml), two third of the blastocysts collected were placed in DMEM medium supplemented with 5 % fetal calf serum. All blastocysts were incubate over night in a humidified atmosphere of 95 % air and 5 % C0 2 at 37 °C.
- mice Pseudopregnant ICR mice were divided into 3 groups, Group 1 mice were implanted with untreated blastocysts, Group 2 mice were implanted with heparanase treated blastocysts, Group 3 mice were implanted with untreated blastocysts following intrauterine injection of 5 ⁇ l of heparanase (4 ⁇ g heparanase per uterine horn).
- the intended experimental design is provided in Table 2 below (Some deviations are noted in Table 3 below):
- recipient ICR female mice (those female mice that developed a copulation plug one day post mating) were anesthetized by intraperitoneal injection of Avertine (0.5 ml/mouse).
- Avertine 0.5 ml/mouse
- a small dorsal midline longitudinal incision was made in the skin.
- the incision was then slid to the left or right until it reached over the ovary and a small incision was made in the body wall.
- the fat pad of the ovary were picked up and the ovary, oviduct and uterus were pulled out through the body wall.
- Using a stereomicroscope a hole was made in the uterus a few mm down from the oviduct-uterus junction.
- a transfer pipette containing approximately 6 blastocysts was then inserted into the hole and the blastocysts were expelled into the uterus. The same steps were repeated for the other horn. The skin was then sutured. For group 3 mice, 5 ⁇ l of heparanase solution (4 ⁇ g) was injected into each uterine horn and 30 minutes thereafter the blastocysts were transferred thereto as described above.
- mice Clinical evaluation of mice was performed once daily, five working days a week, throughout the study period. Animals were monitored for signs of illness or reaction to treatment, until study termination. No such signs were observed. Individual body weights of recipient animals were determined just prior to implantation, and at study termination on day 9 of pregnancy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24085700P | 2000-10-17 | 2000-10-17 | |
US240857P | 2000-10-17 | ||
PCT/IL2001/000950 WO2002032283A2 (en) | 2000-10-17 | 2001-10-15 | Methods of and pharmaceutical compositions for improving implantation of embryos |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1333862A2 true EP1333862A2 (en) | 2003-08-13 |
EP1333862A4 EP1333862A4 (en) | 2004-08-18 |
Family
ID=22908221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01978796A Withdrawn EP1333862A4 (en) | 2000-10-17 | 2001-10-15 | Methods of and pharmaceutical compositions for improving implantation of embryos |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1333862A4 (en) |
AU (1) | AU2002210887A1 (en) |
WO (1) | WO2002032283A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6699672B1 (en) | 1997-09-02 | 2004-03-02 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use research and medical applications |
AU2002216341A1 (en) * | 2000-12-19 | 2002-07-01 | Insight Strategy And Marketing Ltd. | The use of ecm degrading enzymes for the improvement of cell transplantation |
CN100384481C (en) * | 2004-11-03 | 2008-04-30 | 上海市计划生育科学研究所 | Blastocyst implantation related factor and its uses |
CN100415299C (en) * | 2004-12-22 | 2008-09-03 | 上海市计划生育科学研究所 | Correlation factor of blastocyst nidation and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002977A1 (en) * | 1989-08-23 | 1991-03-07 | Hadassah Medical Organization | Wound healing preparations containing heparanase |
WO1999011798A1 (en) * | 1997-09-02 | 1999-03-11 | Insight Strategy & Marketing Ltd. | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
WO1999021975A1 (en) * | 1997-10-28 | 1999-05-06 | The Australian National University | Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
WO2000052149A1 (en) * | 1999-03-02 | 2000-09-08 | Insight Strategy & Marketing Ltd. | Introducing a biological material into a patient |
-
2001
- 2001-10-15 WO PCT/IL2001/000950 patent/WO2002032283A2/en not_active Application Discontinuation
- 2001-10-15 EP EP01978796A patent/EP1333862A4/en not_active Withdrawn
- 2001-10-15 AU AU2002210887A patent/AU2002210887A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002977A1 (en) * | 1989-08-23 | 1991-03-07 | Hadassah Medical Organization | Wound healing preparations containing heparanase |
US5362641A (en) * | 1989-08-23 | 1994-11-08 | Hadassah Medical Organization Kiryat Hadassah | Heparanase derived from human Sk-Hep-1 cell line |
WO1999011798A1 (en) * | 1997-09-02 | 1999-03-11 | Insight Strategy & Marketing Ltd. | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
WO1999021975A1 (en) * | 1997-10-28 | 1999-05-06 | The Australian National University | Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
WO2000052149A1 (en) * | 1999-03-02 | 2000-09-08 | Insight Strategy & Marketing Ltd. | Introducing a biological material into a patient |
Non-Patent Citations (5)
Title |
---|
CARSON DANIEL D ET AL: "Mucin and proteoglycan functions in embryo implantation" BIOESSAYS, vol. 20, no. 7, July 1998 (1998-07), pages 577-583, XP002284179 ISSN: 0265-9247 * |
DEMPSEY L A ET AL: "Heparanase expression in invasive trophoblasts and acute vascular damage" GLYCOBIOLOGY, IRL PRESS,, GB, vol. 10, no. 5, May 2000 (2000-05), pages 467-475, XP002232893 ISSN: 0959-6658 * |
DEMPSEY L A ET AL: "Heparanase, a potential regulator of cell-matrix interactions." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND AUG 2000, vol. 25, no. 8, August 2000 (2000-08), pages 349-351, XP004215172 ISSN: 0968-0004 * |
See also references of WO0232283A2 * |
VLODAVSKY I ET AL: "EXPRESSION OF HEPARANASE BY PLATELETS AND CIRCULATING CELLS OF THE IMMUNE SYSTEM: POSSIBLE INVOLVEMENT IN DIAPEDESIS AND EXTRAVASATION" INVASION METASTASIS, S. KARGER, BASEL, CH, vol. 12, no. 2, March 1992 (1992-03), pages 112-127, XP001106180 ISSN: 0251-1789 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002210887A1 (en) | 2002-04-29 |
WO2002032283A2 (en) | 2002-04-25 |
WO2002032283A3 (en) | 2002-10-31 |
EP1333862A4 (en) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060008892A1 (en) | Methods of and pharmaceutical compositions for improving implantation of embryos | |
Toyoda et al. | Fertilization of rat eggs in vitro by epididymal spermatozoa and the development of eggs following transfer | |
Holm et al. | Embryo viability, duration of gestation and birth weight in sheep after transfer of in vitro matured and in vitro fertilized zygotes cultured in vitro or in vivo | |
CA2856860C (en) | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells | |
Betteridge et al. | Embryo transfer and related techniques in domestic animals, and their implications for human medicine | |
Park et al. | SPAM1/HYAL5 double deficiency in male mice leads to severe male subfertility caused by a cumulus‐oocyte complex penetration defect | |
Revel et al. | Heparanase improves mouse embryo implantation | |
EP1333862A2 (en) | Methods of and pharmaceutical compositions for improving implantation of embryos | |
RU2682318C2 (en) | Compositions and methods for improving milk productivity and reproductive health of mammals based on use of il-8 | |
Hossein et al. | Cloning missy: obtaining multiple offspring of a specific canine genotype by somatic cell nuclear transfer | |
Flores-Foxworth et al. | Interspecific transfer of IVM IVF-derived red sheep (Ovis orientalis gmelini) embryos to domestic sheep (Ovis aries) | |
Melican et al. | Repeat superovulation, non-surgical embryo recovery, and surgical embryo transfer in transgenic dairy goats | |
Ferguson et al. | 136 evidence of a direct effect of P4 on IVF-derived bovine 8-cell embryos | |
Abe et al. | 129 RESPIRATION ACTIVITY OF BOVINE EMBRYOS CULTURED IN SERUM-FREE AND SERUM-CONTAINING MEDIA | |
Cardullo et al. | Function of the egg's extracellular matrix | |
RU2736131C2 (en) | Compositions and methods for improving milk productivity and reproductive health of mammals, based on using il-8 | |
Murakami et al. | Transfer of Inner Cell Mass Cells Derived from Bovine Nuclear Transfer Embryos into the Trophoblast of Bovine In Vitro–Produced Embryos | |
Poleszczuk et al. | 148 AN EFFECT OF MELATONIN ON DEVELOPMENT OF BOVINE EMBRYOS CULTURED IN VITRO UNDER OPTIMAL OR ENHANCED OXYGEN TENSIONS | |
Ock et al. | 145 COMPARISON OF DEVELOPMENT AND QUALITY OF PORCINE EMBRYOS CULTURED IN DIFFERENT OXYGEN CONCENTRATIONS | |
Goda et al. | 137 Effect of flunixin meglumine in co-culture medium on the development of in vitro matured and fertilized bovine embryos | |
Daniaux et al. | 133 INSULIN, TRANSFERRIN AND SELENIUM WITH OR WITHOUT BSA IN A SERUM-FREE CULTURE SYSTEM FOR BOVINE EMBRYO, AND ITS SUITABILITY FOR EMBRYOS CULTURED IN SMALL GROUPS | |
Koch et al. | Rosette inhibition titres in Pig sera before and after recovery of ova and following the transfer of embryos | |
Gandolfi et al. | Expression pattern of Nanog and Par3 genes in in-vitro-derived bovine embryos | |
Wongsrikeao et al. | 151 EFFECTS OF HEXOSES SUPPLEMENTED IN THE MATURATION AND PRE IMPLANTATION MEDIUM ON THE IN VITRO DEVELOPMENT OF PORCINE OOCYTES | |
De La Torre-Sanchez et al. | 135 REGULATION OF GLUCOSE METABOLISM TO DECREASE LIPID CONTENT OF IN VIRTO-PRODUCED BOVINE EMBRYOS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030513 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07H 21/04 B Ipc: 7C 07H 21/02 B Ipc: 7C 12N 15/86 B Ipc: 7C 12N 15/85 B Ipc: 7C 12N 15/11 B Ipc: 7A 61K 38/47 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040701 |
|
17Q | First examination report despatched |
Effective date: 20050329 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSIGHT BIOPHARMACEUTICALS LTD. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080411 |